1. PRESCRIPTION AUDIT AND ADR PROFILE IN PATIENTS WITH LUNG CARCINOMA Jitendra S, Aruna Bhaskar, Shoba Guido, Radheyshyam Dept.of Pharmacology, St.Johns Medical College, Bangalore

2. Lung carcinoma accounts for the total of 30% of the cancers and 28% of the cancer deaths. Lung carcinoma accounts for the total of 30% of the cancers and 28% of the cancer deaths. Chemotherapy is a part of multi- modality treatment in these patients. Chemotherapy is a part of multi- modality treatment in these patients. ADRs happen to be a common occurrence in patients on chemotherapy. ADRs happen to be a common occurrence in patients on chemotherapy. INTRODUCTION

3. OBJECTIVES - To see for the prescription pattern of anti-cancer drugs with lung carcinoma. To see for the prescription pattern of anti-cancer drugs with lung carcinoma. To look for associated ADRs and to define them in accordance with causality assessment. To look for associated ADRs and to define them in accordance with causality assessment.

4. MATERIALS AND METHODS It is a retrospective study carried out from Aug 2001-Sep 2006. It is a retrospective study carried out from Aug 2001-Sep 2006. Data was collected and subjected to Simple descriptive analysis. Data was collected and subjected to Simple descriptive analysis.

5. RESULTS….. Total no. of cases treated on out- patient basis in five years was 68. Total no. of cases treated on out- patient basis in five years was 68. Male : female ratio was 2.5:1. Male : female ratio was 2.5:1. Age range was from 34-70 yrs, average being 55 years. Age range was from 34-70 yrs, average being 55 years. 80% were smokers. 80% were smokers.

6. Outcome on consultation.

7. Average no. of drugs per prescription was 3.55. Average no. of drugs per prescription was 3.55. The maximum drugs prescribed in a given prescription was 11. The maximum drugs prescribed in a given prescription was 11. Generic prescription accounted for 30% of prescribed drugs. Generic prescription accounted for 30% of prescribed drugs.

8. HISTOPATHOLOGICALLY DIAGNOSED CASES

9. Modality of treatments

10. ASSO. OF T/T WITH DIAGNOSIS

11. PRESCRIPTION PATTERN OF DRUGS

12. PRESCRIPTION IN DIFFERENT GROUP OF DRUGS

13. PATTERN OF ANTI-CANCER DRUGS PRESCRIBED

14. ADR PROFILE…. ADRs were reported in 40% of treated patients. ADRs were reported in 40% of treated patients. Type A was the most common type. Type A was the most common type. Hematological adverse events were seen in 70%, GIT 20%,Skin in 10%. Hematological adverse events were seen in 70%, GIT 20%,Skin in 10%.

15. SYSTEMIC ADRS

16. HAEGEMCAR+ETOCARPAC+CARDOC DOC+ CAR GEM+ CAR HB%2(8.1)2(6)1(8)1(8) WBC2(1.7)1(1.2)1(2) MYE26132 PLA2(54)1(30)1(8) HAEMATOLOGY MANIFESTATIONS

17. NON HAEMATOLOGICAL MANIFESTATIONS GEM ETO+ CAR CARPAC+CARDOC DOC+ CAR CAR+ GEM DIA81 VOM34251342 SKIN411 CNS22 CVS111

18. CAUSALITY ASSESSMENT

19. DISCUSSION THERE IS A PREDOMINANCE OF LUNG CARCINOMA AMONG ELDERLY MALE. THERE IS A PREDOMINANCE OF LUNG CARCINOMA AMONG ELDERLY MALE. POLYPHARMACY IS LARGELY PRACTISED IN PRESCRIPTIONS. POLYPHARMACY IS LARGELY PRACTISED IN PRESCRIPTIONS. CHEMOTHEARPY IS THE COMMON MODALITY OF TREATMENT AND PREFERABLY USED IN ADENOCARCINOMA. CHEMOTHEARPY IS THE COMMON MODALITY OF TREATMENT AND PREFERABLY USED IN ADENOCARCINOMA.

20. GEMCITABINE IS PREFFERED NOW. GEMCITABINE IS PREFFERED NOW. PANTAPRAZOLE IS PREFFERED OVER ESMOPRAZOLE. PANTAPRAZOLE IS PREFFERED OVER ESMOPRAZOLE. HAEMATOLOGICAL MANIFESTATIONS ARE COMMON WITH GEMCITABINE. HAEMATOLOGICAL MANIFESTATIONS ARE COMMON WITH GEMCITABINE.

21. VOMITING AND CARDIAC MANIFESTATIONS ARE SEEN WITH DOCETAXEL. VOMITING AND CARDIAC MANIFESTATIONS ARE SEEN WITH DOCETAXEL. POSSIBLE ADVERSE REACTIONS WERE MOST COMMON IN ACCORDANCE WITH CAUSALITY ASSESSMENT. POSSIBLE ADVERSE REACTIONS WERE MOST COMMON IN ACCORDANCE WITH CAUSALITY ASSESSMENT.

22. CONCLUSION SMOKING IS A RISK FACTOR FOR LUNG CARCINOMA. SMOKING IS A RISK FACTOR FOR LUNG CARCINOMA. POLYPHARMACY IS PRACTISED TO REDUCE THE ADVERSE DRUG REACTIONS. POLYPHARMACY IS PRACTISED TO REDUCE THE ADVERSE DRUG REACTIONS. GEMCITABINE AND PANTAPRAZOLE ARE THE NEWLY PREFFERED DRUGS IN REGIMENS BECAUSE OF BETTER EFFICACY AND TOLERABILITY. GEMCITABINE AND PANTAPRAZOLE ARE THE NEWLY PREFFERED DRUGS IN REGIMENS BECAUSE OF BETTER EFFICACY AND TOLERABILITY.

23. THANK YOU……..